Format

Send to

Choose Destination
Rheum Dis Clin North Am. 2017 Feb;43(1):65-78. doi: 10.1016/j.rdc.2016.09.007. Epub 2016 Oct 22.

Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.

Author information

1
Division of Rheumatology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Suite 1.B1, Baltimore, MD, USA. Electronic address: lcappel1@jhmi.edu.
2
Division of Rheumatology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Suite 1.B1, Baltimore, MD, USA.

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly studied and used as therapy for a growing number of malignancies. ICIs work by blocking inhibitory pathways of T-cell activation, leading to an immune response directed against tumors. Such nonspecific immunologic activation can lead to immune-related adverse events (IRAEs). Some IRAEs, including inflammatory arthritis, sicca syndrome, myositis, and vasculitis, are of special interest to rheumatologists. As use of ICIs increases, recognition of these IRAEs and developing treatment strategies will become important. In this review, the current literature on rheumatic and musculoskeletal IRAEs is summarized. The incidence, clinical presentations, and treatment considerations are highlighted.

KEYWORDS:

Arthritis; Immune checkpoint inhibitors; Immune-related adverse events; Malignancy; Sicca syndrome

PMID:
27890174
PMCID:
PMC5127444
DOI:
10.1016/j.rdc.2016.09.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center